ESSENTIAL THROMBOCYTHEMIA

Clinical trials for ESSENTIAL THROMBOCYTHEMIA explained in plain language.

Never miss a new study

Get alerted when new ESSENTIAL THROMBOCYTHEMIA trials appear

Sign up with your email to follow new studies for ESSENTIAL THROMBOCYTHEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 13 Not yet finished but already full! 4 Completed 2 Terminated 1

Promising combo study halted early: hope for advanced blood cancer patients

Disease control Terminated

This study tested a combination of two drugs, ruxolitinib and CPX-351, in people with advanced myeloproliferative neoplasms (MPN), a type of blood cancer that has progressed. The goal was to find the best dose and see if the combination worked better than CPX-351 alone. Only 12 p…

Matched conditions: ESSENTIAL THROMBOCYTHEMIA

Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control

Last updated May 15, 2026 11:57 UTC

ESSENTIAL THROMBOCYTHEMIA

Get alerted when new ESSENTIAL THROMBOCYTHEMIA trials appear

Promising combo study halted early: hope for advanced blood cancer patients